Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer

Immune checkpoint blockade represents a major breakthrough in advanced non-small cell lung cancer (NSCLC) therapy. However, success is limited to a subset of patients and there is a critical need to identify robust biomarkers associated with clinical response. In this study, we assessed whether pre-...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Immunol
Autors principals: Ottonello, Selene, Genova, Carlo, Cossu, Irene, Fontana, Vincenzo, Rijavec, Erika, Rossi, Giovanni, Biello, Federica, Dal Bello, Maria Giovanna, Tagliamento, Marco, Alama, Angela, Coco, Simona, Boccardo, Simona, Vanni, Irene, Ferlazzo, Guido, Moretta, Lorenzo, Grossi, Francesco, Mingari, Maria Cristina, Carrega, Paolo, Pietra, Gabriella
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2020
Matèries:
Immunology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7018763/
https://ncbi.nlm.nih.gov/pubmed/32117275
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.00125
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars